2 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow HS-10382: new trials by email Literature Review of HS-10382 trials Research Report on HS-10382
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016) TERN-701 - Healthy | Phase 1 | Completed | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 8 | 2026-02-25 | 2026-09-24 |
| A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL) MK-4208 - Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase | Phase 1 / Phase 2 | Recruiting | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 330 | 2024-03-26 | 2026-10-15 |
| A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014) Embibatinib, Rabeprazole, Midazolam - Healthy | Phase 1 | Completed | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 196 | 2023-12-21 | 2026-10-22 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Chronic-Phase (1)
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)
United States (3) · Australia (1) · China (1) · France (1) · Germany (1) · Italy (1) · New Zealand (1) · South Korea (1) · Spain (1) · United Kingdom (1)
2023 (1)